ArticleScientific reports2026
The association between pre-existing cardiovascular disease and cancer treatment receipt in a population-based cancer registry.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The association between pre-existing cardiovascular disease and cancer treatment receipt in a population-based cancer registry.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Baseline cardiovascular disease (CVD) has been linked with poorer outcomes for patients with cancer. The precise mechanisms underpinning that are poorly understood but may include reduced treatment receipt. We estimated the association between pre-existing CVD and cancer treatment receipt using population-based cancer registry records. Records of all adults diagnosed with cancer (excluding non-melanoma skin cancer) in Northern Ireland in 2009–2019 were linked with comorbidity and treatment data. The adjusted odds ratios (aOR) of receiving various cancer treatments for patients with previous cardiovascular diagnoses were estimated using multivariable logistic regression, adjusting for established confounders. Subgroup analyses were conducted for combinations of 24 tumour sites, 11 cardiovascular conditions, and 5 cancer treatment modalities. Kaplan-Meier curves and Cox proportional hazards model were used to analyse time to treatment. 81,341 cancer patients were included, with a mean age of 67.1 ± 14.1 years. The most common cancers included were breast (15.8%), lung (14.1%) and colorectal cancer (13.5%). Patients with pre-existing CVD (23.4%) were 30% less likely to receive any cancer treatment than patients without (aOR = 0.70 [95%CI 0.67, 0.73]). This reduction varied between treatment modalities with 30% for chemotherapy (aOR = 0.70 [95%CI 0.67, 0.73]), 28% for radiotherapy (aOR = 0.72 [95%CI 0.66, 0.79]), and 23% for surgery (aOR = 0.77 [95%CI 0.74, 0.80]). Hormone therapy showed no significant overall difference (aOR = 1.02 [95%CI 0.94, 1.11]). At 6 months post-diagnosis, patients with pre-existing CVD had a 14% (0.14 [95%CI 0.13, 0.15]) lower probability of initiating cancer treatment compared to those without. Pre-existing CVD was associated with an overall lower odds of cancer treatment, although the magnitude of this decrement varied according to the primary tumour, treatment modality and the type of CVD. These data present granular population-based insights into the impact of cardiovascular comorbidities on receiving cancer treatment and should be accounted for when reporting survival variations and healthcare policymaking.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.